June 14, 2024Diabetes

736-P: Comparison of Semaglutide vs. Tirzepatide Therapy in Adults with Type 1 Diabetes (T1D)

View Full Paper

Ask AI

Bookmark

Both semaglutide and tirzepatide significantly reduced body weight and improved glycemic control in adults with type 1 diabetes, with tirzepatide showing superior efficacy.
Tirzepatide induced over 10% mean weight loss by 9 months alongside a 0.67% reduction in hba1c, demonstrating greater efficacy than semaglutide in adults with type 1 diabetes.
Linear mixed models evaluated electronic health record data over 9 months, highlighting how glucagon-like peptide receptor agonist therapy can assist type 1 diabetes care.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Real-world study finds greater weight loss and glycemic improvement with tirzepatide than semaglutide in adults with type 1 diabetes, highlighting incretin benefits.

Cite This Study

GEBRE et al. (2024) studied this question.

synapsesocial.com/papers/68e64b41b6db6435875dc473 https://doi.org/10.2337/db24-736-p

View Full Paper

Ask AI

Bookmark

Implication

Real-world study finds greater weight loss and glycemic improvement with tirzepatide than semaglutide in adults with type 1 diabetes, highlighting incretin benefits.

736-P: Comparison of Semaglutide vs. Tirzepatide Therapy in Adults with Type 1 Diabetes (T1D)

Key Points

Discussion

Implication

Cite This Study

736-P: Comparison of Semaglutide vs. Tirzepatide Therapy in Adults with Type 1 Diabetes (T1D)

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider